"On behalf of the Endocrine Society, thank you for the opportunity to submit comments on the Contract Year 2026 Medicare Advantage and Medicare Part D Prescription Drug proposed rule. We are writing to comment specifically on the Part D Coverage of Anti-Obesity Medications (AOMs) (§ 423.100) and Application to the Medicaid Program provision of the rule. Founded in 1916, the Endocrine Society represents approximately 18,000 physicians and scientists engaged in the management and research of endocrine disorders, including obesity. Our members evaluate and treat obesity as well as other weight-related diseases, such as type 2 diabetes. The Society has authored clinical practice guidelines on the Pharmacological Management of Obesity and Pediatric Obesity."
Read the Full Letter